Because survival of patients infected with HIV has improved with HAART, more patients diagnosed with PCNSL may become candidates for chemotherapy. The role of chemotherapy is far from established, however, and there are clear limitations to dose-intensive approaches in the setting of advanced HIV infection. Because of the rarity of this lymphoma, multicenter collaborations are needed to address these and other fundamental management questions. Further insights into the biology of AIDS PCNSL may translate into new and potentially less immunosuppressive treatments.
ASJC Scopus subject areas